Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABSW) Debt to Equity (2020 - 2022)

SAB Biotherapeutics' Debt to Equity history spans 2 years, with the latest figure at $0.02 for Q4 2022.

  • For Q4 2022, Debt to Equity changed N/A year-over-year to $0.02; the TTM value through Dec 2022 reached $0.02, changed N/A, while the annual FY2022 figure was $0.02, N/A changed from the prior year.
  • Debt to Equity reached $0.02 in Q4 2022 per SABSW's latest filing, up from $0.0 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.02 in Q4 2022 to a low of $0.0 in Q4 2020.